Company intelligence / Profile preview
SPH Sine Pharmaceutical Laboratories
- Ownership
- Private
- Development stage
- Other
Overview
SPH Sine is one of China’s largest pharmaceutical manufacturers with nearly 1,000 products across 14 therapeutic areas and 20 dosage forms. It has both generic and innovative drug programs. Recent partnerships include preclinical development using Marinosolv® technology to improve API solubility for inhaled/nasal delivery. The company is active in R&D collaborations on cell therapy and gene therapy through its parent group.
- Therapeutic areas
- PulmonologyNeurologyInfectious DiseasesEndocrinology
- Modalities
- Small moleculeBiologicTraditional Chinese medicineCell therapyGene therapyMonoclonal antibody
- Industry
- Pharma
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on SPH Sine Pharmaceutical Laboratories.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPH Sine Pharmaceutical Laboratories.